Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) EBT (2016 - 2025)

Historic EBT for Sunshine Biopharma (SBFM) over the last 13 years, with Q3 2025 value amounting to -$1.0 million.

  • Sunshine Biopharma's EBT fell 393.57% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year decrease of 5828.03%. This contributed to the annual value of -$5.4 million for FY2024, which is 3060.41% down from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's EBT is -$1.0 million, which was down 393.57% from -$2.0 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's EBT registered a high of $667116.0 during Q4 2021, and its lowest value of -$23.3 million during Q4 2022.
  • Over the past 5 years, Sunshine Biopharma's median EBT value was -$1.2 million (recorded in 2022), while the average stood at -$2.8 million.
  • Data for Sunshine Biopharma's EBT shows a peak YoY increase of 16155.38% (in 2021) and a maximum YoY decrease of 646184.13% (in 2021) over the last 5 years.
  • Sunshine Biopharma's EBT (Quarter) stood at $667116.0 in 2021, then tumbled by 3589.5% to -$23.3 million in 2022, then surged by 95.58% to -$1.0 million in 2023, then crashed by 122.09% to -$2.3 million in 2024, then surged by 55.34% to -$1.0 million in 2025.
  • Its EBT was -$1.0 million in Q3 2025, compared to -$2.0 million in Q2 2025 and -$1.2 million in Q1 2025.